Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents

BACKGROUND: As there are no large-scale reports of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA vaccination in patients with nephrotic syndrome using immunosuppressive agents, we conducted the prospective study. METHODS: SARS-CoV-2 mRNA vaccines were administered to patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamei, Koichi, Ogura, Masao, Sato, Mai, Nishi, Kentaro, Shoji, Kensuke, Funaki, Takanori, Ogimi, Chikara, Ito, Shuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340689/
https://www.ncbi.nlm.nih.gov/pubmed/35913562
http://dx.doi.org/10.1007/s00467-022-05633-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340689/
https://www.ncbi.nlm.nih.gov/pubmed/35913562
http://dx.doi.org/10.1007/s00467-022-05633-y

Ejemplares similares